title: Recurrence of uveitis after discontinuation of infliximab.
abstract: OBJECTIVE
  To evaluate the recurrence of uveitis after discontinuation of infliximab once control of inflammation is achieved.
  
  
  METHODS
  A retrospective cohort study was conducted of patients seen at the Proctor Foundation between 1998 and 2010 who discontinued infliximab after achieving corticosteroid-sparing control by Standardization of Uveitis Nomenclature criteria. The main outcome was the proportion of patients who had a relapse of uveitis.
  
  
  RESULTS
  Eighteen patients attempted to discontinue infliximab after achieving control of inflammation, and 11 patients had a relapse. Median time to relapse was 603 days (95% CI: 85-1461 days). Patients with juvenile idiopathic arthritis (JIA)-associated uveitis (n = 4) relapsed faster (median time to relapse: 76 days, p = 0.002) compared with patients who did not have JIA-associated uveitis (median = 1169 days).
  
  
  CONCLUSIONS
  The majority of patients who achieved control of inflammation on infliximab had a recurrence after discontinuing therapy. Patients with JIA experienced recurrence faster compared to other patients.
authors.affiliation: Francis I. Proctor Foundation and.
authors.forename: Akbar
authors.initials: A
authors.lastname: Shakoor
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Esterberg
authors.forename: Nisha R
authors.initials: NR
authors.lastname: Acharya
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000150:complications / Q000188:drug therapy; D005500:Follow-Up Studies; D056747:Immunomodulation; D000069285:Infliximab; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab